Who
Anne M. Phillips
Director
Company insider
Files Form 4 as: Director, Barinthus Biotherapeutics; Director, vTv Therapeutics; Director, Sagimet Biosciences; Director, Trevena; Director, Amag Pharmaceuticals.
In numbers
- Trades disclosed
- 51
- Buys
- 1
- Sells
- 0
- Bought
- $51K
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 16 Dec 2014
- Last trade
- 9 Sep 2026
- Last filed
- 9 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Sep 2026filed 9 Sep 2026 | Barinthus BiotherapeuticsBiotechnology | SEC FORM 4 Code D | —3,000 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —34,328 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —18,604 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —34,328 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —18,604 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —19,197 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —19,516 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —20,174 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —19,197 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —19,516 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —20,174 at $0.00 | filing |
| 9 Sep 2026filed 9 Sep 2026 | Barinthus BiotherapeuticsBiotechnology | SEC FORM 4 Code D | —3,000 | filing |
| 26 Jun 2026filed 29 Jun 2026 | VTVT vTv Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $210K6,000 at $35.08 | filing |
| 26 Jun 2026filed 29 Jun 2026 | VTVT vTv Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $210K6,000 at $35.08 | filing |
| 12 Jun 2026filed 15 Jun 2026 | SGMT Sagimet Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,567 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | SGMT Sagimet Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,567 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | VTVT vTv Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $66K4,000 at $16.59 | filing |
| 10 Jun 2025filed 11 Jun 2025 | Barinthus Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,174 at $0.00 | filing |
| 9 Jun 2025filed 10 Jun 2025 | SGMT Sagimet Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,268 at $0.00 | filing |
| 1 Aug 2024filed 5 Aug 2024 | SGMT Sagimet Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —113,895 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.